Lindy C, MD’s Post

#ACC24: Results of the EMPACT-MI Trial 📊 Mirvat Alasnag interviews Javed Butler about the results of this trial which he presented in Atlanta. Among patients at increased risk for heart failure after acute MI, treatment with empagliflozin did not lead to a significantly lower risk of first hospitalization for #heartfailure or death. Despite missing its primary endpoint, SGLT-2 inhibitors show potential in heart failure prevention. 🔗 https://lnkd.in/dezJWnu6 #clinicaltrial #latebreakingtrial #cardiology

🎙️NEW #ACC24 Late-Breaker Discussion 💫Dr Gregg Stone joins host Dr Harriette Van Spall to discuss the RELIEVE-HF trial. 📽️Watch in full here👉 https://ow.ly/IFoc50R9YGs 📊V-Wave inter-atrial shunt was safe but did not reduce symptoms or improve HF patient prognosis across 2y across the full range of LVEF. 📊Stratified analysis suggested that implantation is beneficial in #HFrEF, and harmful in patients with #HFpEF. #Cardiology #ClinicalTrial #CardioEd

The effectiveness and safety of sacubitril/valsartan in hospitalized heart failure patients across varying left ventricular ejection fraction levels remain unexplored. Data from the PIONEER-HF and PARAGLIDE-HF trials was pooled, examining treatment outcomes across the EF spectrum (≤40% and >40%) following recent worsening heart failure (WHF). This recently published analysis aims to shed light on sacubitril/valsartan's efficacy, offering valuable insights for managing acute HF episodes. Authors concluded that following stabilization after a recent episode of WHF, patients treated with sacubitril/valsartan experienced significantly greater reductions in plasma NT-proBNP levels and demonstrated improved clinical outcomes compared to those receiving control therapy. This effect was particularly notable across the spectrum of left ventricular ejection fraction ≤60%. These findings were observed in the PIONEER-HF and PARAGLIDE-HF Who Have Been Stabilized and Initiated at the Time of or Within 30 Days Post-decompensation. For details 👇 https://lnkd.in/e99MnE6a #agposts #cardiacupdate #HeartFailure #clinicaltrials #ClinicalResearch #cardiology #cardiologists

It’s interesting to see modern trials that challenge widespread traditional perception on utilization of certain therapies. Take beta-blockers for instance. Most of what we know comes from trials that established them as a cornerstone of medical therapy prior to modern day cath lab/EP lab/HF therapies. Looking at this pharmaceutical therapy as an adjunct to more progressive therapies does not show as meaningful an impact as some of the original studies produced. #healthcare, #pharma, #hospital, #betablocker, #cardiology, #cathlab, #eplab, #epeeps, #heartfailure

🫀Things to know about the REDUCE-AMI trial: “Beta-blockers did not lead to a lower risk of death or myocardial infarction than no beta-blocker treatment.” 👇 what to take into consideration: • No benefit of beta-blockers on mortality over 3.5 yrs in • low-risk post-AMI patients with • LVEF ≥ 50% and • early revascularization. • 35% of subjects presented with a STEMI • metoprolol (62%) and bisoprolol (32%) • Raises curiosity about beta-blocker efficacy in mid-to-high risk patients (❗️) and those with decreased LVEF. 👀 Keep an eye on the REBOOT trial (LVEF ≥ 40%) #reduceami #heart #betablockers #myocardialinfarction #nejm #cardiovascular #cardiology #mortality

This subject is of significant interest as it requires a comprehensive understanding of the molecular signaling framework underlying this threshold.

Most trials that have shown a benefit of beta-blocker treatment after myocardial infarction included patients with large myocardial infarctions and were conducted in an era before modern biomarker-based diagnosis of myocardial infarction and treatment with percutaneous coronary intervention, antithrombotic agents, high-intensity statins, and renin–angiotensin–aldosterone system antagonists. The REDUCE-AMI trial concludes that, among patients with an acute myocardial infarction and preserved ejection fraction, long-term treatment with beta-blockers did not lead to a lower risk of death or myocardial infarction than no beta-blocker treatment. Learn more about this study by reading the Original Article "Beta-Blockers after Myocardial Infarction and Preserved Ejection Fraction": https://nej.md/4akVhRx #ClinicalTrials #Cardiology

We're delighted to have Sem Rikken present "TCT 329: Pharmacokinetics of 14C-Labeled Zalunfiban (RUC-4) Suggests That No Dose Adjustment Is Necessary for Impaired Renal Function". 📅 Date: Wednesday, October 30, 2024 ⏰ Time: 8:45 AM 📍 Session: CKD, AKI, and Contrast Management-2 | TCT2024 This presentation will be on behalf of Robert B. MacArthur, PharmD, MS, BCSCP, Barry Coller, C. Michael Gibson, M.S., M.D., Chris Granger, Gilles Montalescot, Jur ten Berg, and Arnoud van 't Hof. 💡 Exciting new data emerging about #zalufiban and its potential role in treating patients with heart attacks. #TCT2024 #hearthealth #cardiology #pharmacokinetics

Echocardiogram of a patient whose primary diagnosis is HCC (hepatocellular carcinoma) HCC is very well known for its agressive nature and once intracardiac involvement is established which is usually rare, the prognosis is very poor. Understanding non-cardiac cases and their secondary effects on the heart is crucial for easier diagnosis. This knowledge allows us to consider a broader range of possibilities and provide more comprehensive care to our patients. #Cardiology #Healthcare”

The AEGIS-II trial has shown no benefit from treating #myocardialinfarction patients with #ApoA1 after the event. The trial was testing the hypothesis that increasing #HDLcholesterol (ApoA1 is the #lipoprotein transporting #cholesterol in #HDL particles) would increase the reverse transportation of cholesterol out of the #atheroma plaques. If the hypothesis was true, a reduction of atherosclerotic risk would mean a reduction of #cardiovascular events (e.g. #acutecoronarysyndrome and #stroke). However, the study shows no difference between the ApoA1 and the placebo groups. Despite the disappointing results of the AEGIS-II trial, this editorial at #NEJM calls for reconceptualizing the investigation rather than abandoning it. The authors place relevant questions about duration of therapy, the selection of population who would benefit from therapy (e.g. population with low baseline cholesterol efflux) and length of follow up period. https://lnkd.in/dwBQfxQX #cardiology #prevention #lipids #atherosclerosis